Return to Listing

18 result(s) for Gastrointestinal Cancers

PI Name Protocol # Title
Brett Sheppard IRB00003609 Oregon Pancreas Tissue Registry
Kevin Billingsley IRB00005222 Oregon Liver Tumor Registry
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Daniel Herzig IRB00011161 A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
Jeremy Cetnar STUDY00015218 A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120mg Plus BSC Vs Placebo Plus BSC For Tumor Control In Subjects With Well-Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors
Gina Vaccaro STUDY00015495 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Brett Sheppard STUDY00015705 The OHSU Pancreas Community Registry
Skye Mayo STUDY00016033 A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
Gina Vaccaro STUDY00016058 CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
Gina Vaccaro STUDY00016107 ARRAY-818-302: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
Gina Vaccaro STUDY00016255 INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Charles Lopez STUDY00016609 AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Rodney Pommier STUDY00016689 An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment
Eric Anderson STUDY00016890 A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
Nima Nabavizadeh STUDY00017075 [NCI CIRB] RTOG 0848: A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R)and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Charles Lopez STUDY00017094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Charles Thomas STUDY00017143 Pilot Study for the Identification of Candidate Urinary Biomarkers for Hepatocellular Carcinoma
Jackilen Shannon STUDY00017573 Focus Groups for Widespread Testing for Cancer Risk Syndromes
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080